重新思考卵巢癌II：降低高级别浆液性卵巢癌的死亡率
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
作者信息
Bowtell David D, Böhm Steffen, Ahmed Ahmed A, Aspuria Paul-Joseph, Bast Robert C, Beral Valerie, Berek Jonathan S, Birrer Michael J, Blagden Sarah, Bookman Michael A, Brenton James D, Chiappinelli Katherine B, Martins Filipe Correia, Coukos George, Drapkin Ronny, Edmondson Richard, Fotopoulou Christina, Gabra Hani, Galon Jérôme, Gourley Charlie, Heong Valerie, Huntsman David G, Iwanicki Marcin, Karlan Beth Y, Kaye Allyson, Lengyel Ernst, Levine Douglas A, Lu Karen H, McNeish Iain A, Menon Usha, Narod Steven A, Nelson Brad H, Nephew Kenneth P, Pharoah Paul, Powell Daniel J, Ramos Pilar, Romero Iris L, Scott Clare L, Sood Anil K, Stronach Euan A, Balkwill Frances R
机构信息
Cancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
出版信息
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
高级别浆液性卵巢癌（HGSOC）占卵巢癌死亡病例的70-80%，并且几十年来总体生存率并未显著改变。在这篇观点文章中，我们概述了一系列研究重点，我们认为这些重点将降低发病率并改善患这种疾病女性的治疗结果。这份HGSOC的“路线图”是在2015年1月卵巢癌行动会议上进行广泛讨论后确定的。
相似文献
Nat Rev Cancer. 2015-11
Cancer Epidemiol Biomarkers Prev. 2019-4-9
J Natl Cancer Inst. 2018-3-1
引用本文的文献
本文引用的文献
Nature. 2015-5-28
Nature. 2015-4-16
J Clin Oncol. 2015-4-20
Ann Surg Oncol. 2015-11
Nat Rev Clin Oncol. 2015-4
Zotero 插件